Zobrazeno 1 - 10
of 14
pro vyhledávání: '"E. Linardou"'
Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records of patients with cancer a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::60b68396854ba135951a4a2886c6c74c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999633
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999633
Background We evaluated real-world clinical outcomes and toxicity data and assessed treatment-related costs in patients with advanced breast cancer who received treatment with cyclin-dependent kinase inhibitors (CDKi). Patients and methods We conduct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::5b59cb3345110abec116bb9e4efc4068
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078145
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078145
Autor:
V. Barbounis, Sofia Baka, E. Bournakis, I. Bankousli, A. Anagnostopoulos, Georgios Pentheroudakis, Christos Christodoulou, Anna Koumarianou, S. Kakolyris, E. Diamantidou, E. Linardou, V. Georgoulias, Nikolaos Androulakis, Gerassimos Aravantinos, G. Koumakis, E. Maragkouli, Christos Emmanouilidis, A. Athanasiadis, PA Kosmidis, Alexandros Ardavanis, C. Kalofonos, Christos N. Papandreou, P. Makrantonakis, C. Andreadis, D. Mavroudis, D. Daliani, Ourania Katopodi, Stavros D. Peroukidis, I. Syrios, Ilias Athanasiadis, M. Liontos, S. Karageorgopoulou, A Polyzos, G. Lypas, Z. Saridaki, I. Korantzis, Michail Nikolaou, G. Kesisis, I. Boukovinas, E. Saloustros, A. Fassas, N. Tsoukalas, P. Sarikaki, N. Ziras, I. Varthalitis, I. Xanthakis, I. Mpompolaki, I. Sgouros, C. Stathopoulos, P. Papakotoulas
Publikováno v:
Journal of Global Oncology. 4:74s-74s
Background: State health insurance authorities in Greece do not reimburse genetic testing for cancer predisposition. The Hellenic Society of Medical Oncology has launched and carries out a national program covering genetic testing for BRCA1/2 mutatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3926ce575f754a9fc256e85de76dc32
https://doi.org/10.1200/jgo.18.55800
https://doi.org/10.1200/jgo.18.55800
Autor:
Aristidis Polyzos, C. Christodoulou, Charalambos Kouroussis, George Fountzilas, Helen Gogas, E. Linardou, H. P. Kalofonos, E. Briassoulis, T. G. Iconomou, S. Chalkidou, Dimitris Bafaloukos, P. Panagiotou, Eleni Efstathiou, Dimosthenis Tsoutsos
Publikováno v:
Annals of Oncology. 16:950-957
Purpose: Temozolomide (TMZ) is an oral alkylating agent that produces methyl adducts at the 0.6 position of guanine. The methyl adducts are removed by the DNA repair enzyme AGAT. As demonstrated by in vitro studies, cisplatin (CDDP) is able to down-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0bc60e4cfe42cf15e1227809968911
https://doi.org/10.1093/annonc/mdi190
https://doi.org/10.1093/annonc/mdi190
Autor:
Gerassimos Aravantinos, C.A. Kostakopoulos, George Fountzilas, K. Dimopoulos, D. Picramenos, Th. Giannakakis, D.V. Skarlos, E. Linardou, Ioannis Kastriotis, C. Christodoulou
Publikováno v:
European Urology. 31:420-427
Objectives: We conducted a phase II study in order to assess the efficacy and toxicity of Carbo-MVE (carboplatin 250 mg/m 2 i.v. day 1, methotrexate 25 mg/m 2 i.v. days 1, 15 and 22, vinblastine 2.5 mg/m 2 i.v. days 1, 15 and 22 and epirubicin 25 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e0817eb11dd215ffda01c8d2378c01e
https://doi.org/10.1159/000474500
https://doi.org/10.1159/000474500
Background: Taxanes are established in the treatment of metastatic breast cancer (MBC) and early breast cancer (EBC) as potent chemotherapy agents. However, their therapeutic usefulness is limited by de-novo refractoriness or acquired resistance, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::f402a89b37230a741f60654041c4eb64
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3154409
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3154409
Autor:
Pallis, A. Briasoulis, E. Linardou, H. Papadimitriou, C. and Bafaloukos, D. Kosmidis, P. Murray, S.
Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors (TKIs) of the EGFR tyrosine kinase. There are, however, patients with EGFR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2a90597fd77f78a7002a110a3b8150af
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3149064
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3149064
The analyses of composite recipes are frequently missing in nutrient databases and their inclusion presupposes expensive and fairly complicated chemical analyses. The nutritional composition of traditional Greek composite foods was determined through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::a3e13de75a34a1ff053411feefd69a60
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3010912
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3010912
Autor:
D V, Skarlos, G, Aravantinos, E, Linardou, C A, Kostakopoulos, I, Kastriotis, C, Christodoulou, D, Picramenos, T, Giannakakis, K, Dimopoulos, G, Fountzilas
Publikováno v:
European urology. 31(4)
We conducted a phase II study in order to assess the efficacy and toxicity of Carbo-MVE (carboplatin 250 mg/m2 i.v. day 1, methotrexate 25 mg/m2 i.v. days 1, 15 and 22, vinblastine 2.5 mg/m2 i.v. days 1, 15 and 22 and epirubicin 25 mg/m2 day 1). The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d72c5ef3aac7a82c3fa8a3331e0a554c
https://pubmed.ncbi.nlm.nih.gov/9187901
https://pubmed.ncbi.nlm.nih.gov/9187901
Autor:
E. Linardou, C. Nicolaides, C. Bacoyiannis, G. Fountzilas, P. Kosmidis, G. Klouvas, Kostas N. Syrigos, Aristotle Bamias, Ioannis Boukovinas, Thomas Makatsoris
Publikováno v:
Journal of Clinical Oncology. 27:e19035-e19035
e19035 Background: The optimal treatment of patients with advanced NSCLC and PS 2 is not well established. Our group has shown that single agent is equally effective to doublets. Purpose of this study was to compare efficacy and toxicity of two singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b652e09548f3a8859b1e350d5667d25
https://doi.org/10.1200/jco.2009.27.15_suppl.e19035
https://doi.org/10.1200/jco.2009.27.15_suppl.e19035